Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Ans – page 34

1 400 clinical trials in Ans, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Ans at a glance
1 400
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 400 trials in Ans

Open in trial search

Study on Midostaurin and Gemtuzumab Ozogamicin for Adults with Acute Myeloid Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Technische Universitat Dresden

Study on Doxapram for Treating Apnea in Preterm Newborns

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Doxapram Hydrochloride Monohydrate
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Hereditary ataxia+1

Recruiting

Study on the Safety of VO659 for Patients with Spinocerebellar Ataxia Types 1, 3, and Huntington's Disease

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:VO659
  • Sponsor:Vico Therapeutics B.V.

Study on Treating Chronic Lymphocytic Leukemia with Venetoclax and Acalabrutinib for Patients Whose Disease Has Returned After Initial Treatment

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using Daunorubicin, Mitoxantrone, and a Drug Combination

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Cytarabine
  • Sponsor:Vastra Gotalandsregionen

Study on Pembrolizumab and Radiotherapy for Patients with Limited Spread of Head and Neck Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Ependymoma

Recruiting

Study on Ependymoma Treatment in Children, Adolescents, and Young Adults Using Cisplatin, Cyclophosphamide, Etoposide, and a Drug Combination

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Cisplatin
  • Sponsor:Centre Leon Berard

Study of drug combinations including irinotecan, ifosfamide, vincristine, dactinomycin, regorafenib and other agents for children and adults with rhabdomyosarcoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:The University Of Birmingham

Study of Pembrolizumab and V940 for Treating Non-Small Cell Lung Cancer in Patients with Resectable Stage II to IIIB (N2) Not Achieving Complete Response

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Study on the Safety and Benefits of Recombinant Human Plasma Gelsolin for Patients with Moderate-to-Severe Acute Respiratory Distress Syndrome (ARDS)

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Human Plasma Gelsolin, Recombinant
  • Sponsor:Bioaegis Therapeutics Inc.

Study on Methotrexate and Prednisone for Treating Lung Sarcoidosis in Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Methotrexate
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Study on Long-term Safety of JNJ-81201887 for Patients with Geographic Atrophy Due to Age-related Macular Degeneration

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Onzemipgene parvec
  • Sponsor:Janssen Cilag International

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Ans

What the registry says about research in the country

01 Gastroenterology Research

Clinical investigations focusing on proton pump inhibitor (PPI) de-prescribing strategies for patients with chronic usage patterns. The research explores innovative approaches to manage functional dyspepsia and related conditions.

  • PPI Usage Optimization
  • Digestive Health Management
  • Acid Reflux Treatment

This primary care study evaluates different therapeutic approaches, including on-demand medication use and alternative treatment formulations, to improve patient outcomes in digestive health management.

02 Primary Care Innovation

Groundbreaking research in medication management strategies, specifically targeting long-term PPI use in primary care settings. The study compares various approaches to reduce unnecessary medication dependency.

  • Medication De-prescribing
  • Patient-Centered Care
  • Treatment Optimization

The research aims to establish more effective protocols for managing common digestive conditions while minimizing long-term medication use.

03 Therapeutic Alternatives

Investigation into alternative treatment options for managing heartburn and related gastrointestinal conditions. The study explores the effectiveness of different therapeutic approaches.

  • Alternative Treatments
  • Symptom Management
  • Treatment Comparison

This research evaluates the comparative effectiveness of various treatment strategies, including alginate formulations and flexible dosing schedules.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.